Cite
MLA Citation
T. Dörner et al.. “OP0302 IANALUMAB (VAY736), A DUAL MODE OF ACTION BIOLOGIC COMBINING BAFF RECEPTOR INHIBITION WITH B CELL DEPLETION, REACHES PRIMARY ENDPOINT FOR TREATMENT OF PRIMARY SJOGREN'S SYNDROME.” Annals of the rheumatic diseases, vol. 79, n.d., pp. 187–188. http://access.bl.uk/ark:/81055/vdc_100144724391.0x000040